Global Excellence 2019

242 Acquisition International - Global Excellence 2019 Jun19456 8 Acquisition I ternational - Issue 10 2019 Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions Top Blood and Marrow Transplant and Immunotherapy programs depend on Title21 Health Solution’s (Title21) technology to manage the patient, product and process data from collection to infusion. From reporting to analytics, Title21 provides all the critical data at your fingertips so the right person has the right data at the right time to make the right decisions. This allows Medical Technologists, Technical and Medical Directors to focus on higher-value work, and ultimately the patient, rather than chasing down paperwork and people. Earlier this year, Title21 was selected as the Most Outstanding Cell Therapy Software Provider for 2019 by AI’s Global Excellence Award. We had a chance to catch up with Lynn Fischer, the CEO at Title21 who provided us with a detailed insight into the award-winning software provider. ince their inception, Tile21’s Cloud and on- premise software manages critical patient, product and process data for cell and gene therapy, immunotherapy and regenerative medicine to ensure quality, compliance and traceability. Programs that implement Title21 solutions find they can scale more effectively to treat more patients and can also translate products more quickly and efficiently from bench to bedside, delivering the latest innovative therapies to patients faster and more safely. Title21 has served FDA-regulated life science companies for many years with quality management software, so Title21’s experience has been of great service to the cell therapy segment. “Our technology is extremely flexible due to its configurability on the front end. That means that we can maintain a single code base while meeting each cancer center or cell manufacturers’ specific requirements.” S Jun19456